Form 4: Masimo Director Charles Dadswell Receives Equity Awards

Masimo Corporation's Director, Charles Dadswell, received grants of Restricted Stock Units and Non-Qualified Stock Options on August 18, 2025.

Summary

• Charles Dadswell, a Director of Masimo Corporation (MASI), was granted equity awards on August 18, 2025.
• The awards include 2,273 Restricted Stock Units (RSUs), each representing the contingent right to receive one share of common stock.
• The RSU award vests ratably over four years, with 25% vesting on each anniversary of the grant date.
• Additionally, 5,104 Non-Qualified Stock Options were granted with an exercise price of $153.93 per share.
• The stock options vest over a five-year period, with 20% of the shares subject to the option vesting on each anniversary of the grant date.
• Both the RSUs and the stock options have an expiration date of August 18, 2035.

Sentiment

Score: 7

Explanation: The grant of equity awards to a director is a positive development as it aligns their interests with shareholders, promoting long-term value creation. This is a routine compensation event, not indicative of extraordinary positive or negative news.

Positives

• The grant of equity awards to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• Equity compensation is a standard practice for attracting and retaining qualified board members.

Future Outlook

The equity awards are designed to incentivize long-term performance, with vesting schedules extending over four and five years, aligning the director's future compensation with the company's stock performance.

Industry Context

Equity grants to directors and executives are a common and widely accepted practice across various industries, including medical technology, to align leadership incentives with shareholder value creation and promote long-term commitment.

Comparison to Industry Standards

• The structure of these equity grants, including the mix of RSUs and stock options and their multi-year vesting schedules, is consistent with typical executive and director compensation packages observed in the medical technology sector.
• Companies like Medtronic (MDT), Abbott Laboratories (ABT), and Stryker (SYK) frequently utilize similar long-term incentive plans to compensate their non-employee directors, often involving a combination of restricted stock and stock options to balance retention and performance incentives.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with shareholder value, potentially leading to more focused long-term decision-making.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The RSUs will vest in 25% increments on each anniversary of the August 18, 2025 grant date over four years.
• The stock options will vest in 20% increments on each anniversary of the August 18, 2025 grant date over five years.

Key Dates

Keywords

Masimo Corporation, MASI, Charles Dadswell, Director, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Form 4, Corporate Governance